US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

203.47

+0.83000.41%

Volume:180.67K

Turnover:36.85M

Market Cap:10.31B

PE:32.24

High:205.30

Open:203.96

Low:203.39

Close:202.64

52wk High:217.12

52wk Low:138.79

Shares:50.65M

Float Shares:50.65M

Volume Ratio:0.88

T/O Rate:0.36%

Dividend:0.41

Dividend Rate:0.20%

EPS(TTM):6.31

EPS(LYR):-1.4940

ROE:24.54%

ROA:0.10%

PB:1.27

PE(LYR):-136.19

Loading ...

Overview Company News Filings

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Exchange-Traded Funds Rise as US Equities Advance After Midday

MT Newswires Live

Sector Update: Healthcare

MT Newswires Live

Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

Sector Update: Healthcare

MT Newswires Live

Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

JW Cayman Therapeutics FY26 H1 IFRS Loss Narrows 81.14% to RMB 50.4 Million; Revenue Rises 4.7% to RMB 111.4 Million

Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints

AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients

MT Newswires Live

Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026

Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.

AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial

Amgen - Tezspire Safety Profile Consistent with Approved Indications

THOMSON REUTERS

Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints

THOMSON REUTERS

Biotron Posts Wider Annual Loss but Boosts Asset Backing Amid Material Uncertainty

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/IBB/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"iShares Biotechnology ETF","latestPrice":203.47,"timestamp":1789136734327,"preClose":202.64,"halted":0,"volume":180669,"delay":0,"changeRate":0.004095933675483678,"floatShares":50650000,"shares":50650000,"eps":6.311863,"marketStatus":"Trading","change":0.83,"latestTime":"09-11 10:25:37 EDT","open":203.96,"high":205.3,"low":203.39,"amount":36852114.650340006,"amplitude":0.009426,"askPrice":203.48,"askSize":23,"bidPrice":203.43,"bidSize":13,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789156800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":202.64,"sharesOutstanding":49450000,"nav":205.458405,"aum":10437286974,"dividendRate":0.001992,"bidAskSpread":0.000306,"preHourTrading":{"tag":"盘前","latestPrice":204.63,"preClose":202.64,"latestTime":"09:25 EDT","volume":602,"amount":123106.38130000001,"timestamp":1789133112066,"change":1.99,"changeRate":0.00982,"amplitude":0.017917},"postHourTrading":{"tag":"盘后","latestPrice":202.3531,"preClose":202.64,"latestTime":"19:44 EDT","volume":31689,"amount":6417724.8659,"timestamp":1789083850615,"change":-0.2869,"changeRate":-0.001416,"amplitude":0.003158},"volumeRatio":0.881294,"impliedVol":0.2033,"impliedVolPercentile":0.1155},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":50650000,"roa":"0.10%","roe":"24.54%","lyrEps":-1.493977,"volumeRatio":0.881294,"shares":50650000,"dividePrice":0.4053,"high":205.3,"amplitude":0.009426,"preClose":202.64,"low":203.39,"week52Low":138.785,"pbRate":"1.27","psRate":"247.95","week52High":217.12,"institutionHeld":0,"latestPrice":203.47,"committee":-0.277778,"eps":6.311863,"divideRate":0.001992,"volume":180669,"delay":0,"ttmEps":6.311863,"open":203.96,"prevYearClose":168.77,"prevWeekClose":211.92,"prevMonthClose":209.05,"prevQuarterClose":190.19,"fiveDayClose":213.81,"twentyDayClose":198.94,"sixtyDayClose":171.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"},{"date":"2025-03-18","symbol":"IBB","amount":0.121169,"announcedDate":"2025-03-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-18","defaultRemindTime":1742304600000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-03-18","currency":"USD","dateTimestamp":1742270400000,"payDate":"2025-03-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-26","recordDate":"2016-09-28","paymentDate":"2016-09-30","value":0.0858219,"currency":"USD"},{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662036301","title":"US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036301","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036301?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867441,"startTime":"0","endTime":"0","summary":"US FDA approves Gilead's once-daily combination pill for HIV treatmentAug 27 -The U.S. Food and Drug Administration has approved Gilead Sciences'GILD.Oonce daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the company said on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O24M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","LU0965508806.USD","LU1061106388.HKD","IE00B19Z3581.USD","BK4588","LU2357627491.SGD","GILD","LU1934455863.HKD","TBXU","TMED","SG9999015952.SGD","LU0861579265.USD","BK4583","IE00B7SZLL34.SGD","BBH","LU1037948897.HKD","BK4139","LU2324357040.USD","LU1778281490.HKD","LU0965509010.AUD","LU1037948541.HKD","BK4585","MEDI","BK4566","IE0002270589.USD","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU0882574055.USD","LU1585245621.USD","LU0320765992.SGD","LU1023059063.AUD","IBBQ","LU2468319806.SGD","LU0122379950.USD","LU0058720904.USD","LU0965509101.SGD","LU1934455277.USD","IE00B19Z3B42.SGD","LU1066051498.USD","LU1839511570.USD","LU0889565916.HKD","SG9999015945.SGD","LU0114720955.EUR","BK4578","BMED","LU1674673428.USD","LU0234570918.USD","IBB","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036807","title":"U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036807?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:47","pubTimestamp":1787867220,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA7M9KZ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1934455277.USD","IBBQ","BK4550","LU2089984988.USD","GILD","BIB","LU0861579265.USD","LU1934455863.HKD","TBXU","BMED","LU0882574055.USD","BK4588","LU1061106388.HKD","LU0965509010.AUD","LU2112291526.USD","SG9999015945.SGD","IE00B3T34201.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","BK4566","LU2087621335.USD","SG9999015978.USD","LU1066051498.USD","LU0320765992.SGD","BK4578","LU1571399168.USD","LU1057294990.SGD","LU0289739699.SGD","MEDI","IE00B7SZLL34.SGD","LU1839511570.USD","TMED","LU1066053197.SGD","IBB","IE00BKVL7J92.USD","BK4532","LU1430594728.SGD","LU0234570918.USD","BK4568","LU0889565916.HKD","LU1778281490.HKD","LU1037948897.HKD","LU0109394709.USD","LU1934455194.USD","BBH","BK4583","LU2468319806.SGD","LU0965509283.SGD","IE00B19Z3B42.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033626","title":"Moderna Inc. Stock Slips 4.6%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033626?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:34","pubTimestamp":1787862840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. slid 4.6% to $142.77 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.6% to 26,541.35 and the Dow Jones Industrial Average rising 0.2% to 53,569.44.This was the stock's second consecutive day of losses.Moderna Inc. closed 19.2% short of its 52-week high of $176.66, which the company reached on August 19th.The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 1.6% to $265.77, Pfizer Inc. fell 1.0% to $28.02, and Gilead Sciences Inc. rose 0.52% to $148.86.Trading volume totaled 24.9 million, compared to the 50-day average of 16.4 million.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509283.SGD","LU1934455277.USD","IE00B7SZLL34.SGD","LU0109394709.USD","BK4583","TMED","LU0861579265.USD","LU0114720955.EUR","SG9999015986.USD","BK4534","LU2468319806.SGD","LU1674673691.USD","MRNX","LGHT","LU0965509010.AUD","LU1571399168.USD","WDNA","MEDI","SG9999015952.SGD","LU2357627491.SGD","LU2324357040.USD","LU1934455194.USD","MRNA","TBXU","LU1061106388.HKD","BK4533","BK4588","IE00BKVL7J92.USD","LU0965508806.USD","MRNY","GNOM","LU0058720904.USD","BK4550","LU1037948541.HKD","IBBQ","LU1674673428.USD","LU1066053197.SGD","IE00B19Z3581.USD","SG9999015945.SGD","GILD","BK4551","BK4568","LU0320765992.SGD","LU0889565916.HKD","BIB","IDNA","IBB","BBH","BK4139","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662828380","title":"Exchange-Traded Funds Rise as US Equities Advance After Midday","url":"https://stock-news.laohu8.com/highlight/detail?id=2662828380","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662828380?lang=en_us&edition=fundamental","pubTime":"2026-08-28 01:09","pubTimestamp":1787850562,"startTime":"0","endTime":"0","summary":"Broad Market IndicatorsBroad-market exchange-traded funds IWM and IVV were higher. Actively traded Invesco QQQ Trust (QQQ) added 1.2%.US equity indexes rose after Nvidia's (NVDA) strong fiscal Q2 resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VHT","SPDN","XLE","NVDA","IYH","SQQQ","ETH",".SPX","IYE","BETH","VIS","XLV","XLK","RTH","XLP","USO","IYJ","QQQ","RSPU","SOXX","FDN","EETH","BITO","VDC","XLY","STCE","XLF","IBB","RTH.AU","VHT.AU","IYW","XLI","XRT",".IXIC","UNG","FAZ","STT","SLV","FAS","ARTY","SPYM",".DJI","XSD","IYK","ARKY","BTF","GLD","IGM","BETE","SPHD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662017084","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2662017084","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662017084?lang=en_us&edition=fundamental","pubTime":"2026-08-28 01:03","pubTimestamp":1787850204,"startTime":"0","endTime":"0","summary":"Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF  shedding 0.7%.The iShares Biotechnology ETF  was fractionally lower.In corporate news, Moderna  shares fell 5.6% after it said Thursday it plans to offer $2 billion worth of convertible senior notes due 2032 in a private placement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LGHT","BK4533","XLV","IBB","BK4585","BK4581","LU0128526141.USD","BK4139","BK4137","BK4501","BK4548","FDN","LU0029874061.USD","MRNA","GNOM","IDNA","LABU","WDNA","HCSG","BK4532","BK4551","MRNX","STT","XBI","MRNY","BK4534","BK4588","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084187","title":"Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084187","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084187?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:31","pubTimestamp":1787848308,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has started a new Phase 1 trial called “A Phase 1, Open-La...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","IE0002141913.USD","LU0889565916.HKD","TBXU","LU1061106388.HKD","PBE","IE00B4R5TH58.HKD","IBB","IE00B2B36J28.USD","LU1023059063.AUD","AMGN","LU2242646821.SGD","SG9999001440.SGD","BBC","BK4581","LU0058720904.USD","PJP","LU1057294990.SGD","LU1571399168.USD","BK4585","BK4566","LU2089984988.USD","BK4534","LU2242652126.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4139","IE00BJJMRZ35.SGD","BK4599","LU0868494617.USD","LU1983299246.USD","LU0122379950.USD","LU2112291526.USD","BBH","BK4533","IE0009355771.USD","BK4588","BIB","IBBQ","LU0289739699.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662813780","title":"Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662813780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662813780?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:20","pubTimestamp":1787844046,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verrica Pharmaceuticals (VRCA) and Amgen (AMGN). Verrica Pharmace...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","LU1023059063.AUD","IE0002141913.USD","LU0868494617.USD","BK4581","BK4137","BBH","LU1571399168.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU0122379950.USD","LU2468319806.SGD","BK4007","PJP","SG9999001440.SGD","BK4533","LU2242652126.USD","LU2089984988.USD","LU1983299246.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","TBXU","LU0058720904.USD","XBI","BIB","LU1061106388.HKD","LU2112291526.USD","LABU","BK4566","LU0289739699.SGD","BK4585","LU1057294990.SGD","HCSG","PBE","LU0029874061.USD","IBB","AMGN","BK4588","IE00B2B36J28.USD","XLV","BK4139","LU0109394709.USD","IE0009355771.USD","LU2242646821.SGD","LU0889565916.HKD","BK4534","BK4599","VRCA","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084083","title":"HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084083","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839287,"startTime":"0","endTime":"0","summary":"HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionHBM Holdings posted revenue of US$122.49 million for the six months ended June 30, 2026, up 20.9","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL77D5HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0109394709.USD","LU0058720904.USD","IE00B4R5TH58.HKD","BK4585","LU1061106388.HKD","LU2112291526.USD","LU2089984988.USD","BIB","BK4533","LU0289739699.SGD","BK4139","LU2468319806.SGD","BK1574","IE00BJJMRZ35.SGD","LU1057294990.SGD","PJP","LU1023059063.AUD","BK4588","IE00B2B36J28.USD","BK1583","LU2242652126.USD","02142","LU0889565916.HKD","IE00BFTCPJ56.SGD","BK4566","PBE","LU1571399168.USD","BBH","AMGN","BK1161","IBB","LU0320765992.SGD","TBXU","IE0009355771.USD","LU1983299246.USD","BK4599","IBBQ","LU0868494617.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU0122379950.USD","SG9999001440.SGD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662007177","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2662007177","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662007177?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:01","pubTimestamp":1787835662,"startTime":"0","endTime":"0","summary":"Healthcare stocks were declining pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF  0.7% lower and the iShares Biotechnology ETF  down 0.5%.Novo Nordisk  said China's National Medical Products Administration has accepted its marketing application for the oral version of its weight-loss drug Wegovy, Reuters reported. Novo Nordisk stock was down more than 2% premarket.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVOC","NVO","XLV","BK4588","OZEM","XBI","IBB","IE00BZ1G4Q59.USD","NVOX","NVOH","LABU","IE00BKVL7J92.USD","BK4532","LU1093756325.SGD","PPH","THNR","BK4585","LU0154236417.USD","LU1093756168.USD","BK4007","BK4599","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662013447","title":"Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements","url":"https://stock-news.laohu8.com/highlight/detail?id=2662013447","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662013447?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:15","pubTimestamp":1787829352,"startTime":"0","endTime":"0","summary":"Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1267930573.SGD","LU0432979614.USD","BIB","LU0708994859.HKD","BK4533","BK4568","IE00B4R5TH58.HKD","BK4581","LU2237443978.SGD","AZN","LU2089984988.USD","BK4585","BK4588","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2417539215.USD","IE0002141913.USD","LU0289739699.SGD","LU2242646821.SGD","LU1829250122.USD","IBB","PJP","LU2237443465.HKD","LU1057294990.SGD","LU2237443382.USD","LU0029864427.USD","BK4139","IE0009355771.USD","LU2237443622.USD","TBXU","IE00BFTCPJ56.SGD","LU0128525929.USD","AMGN","LU1023059063.AUD","AZNH","LU2456880835.USD","BK4007","LU0868494617.USD","BBH","LU2236285917.USD","IE00BJJMRZ35.SGD","PBE","BK4534","IBBQ","LU2242652126.USD","LU0122379950.USD","LU2462157665.USD","LU2468319806.SGD","BK4566","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708043","title":"China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708043","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708043?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:08","pubTimestamp":1787825320,"startTime":"0","endTime":"0","summary":"China's JW Therapeutics interim revenue rises 4.7% on Carteyva salesOverviewChina cell immunotherapy developer's interim revenue grew 4.7% yr/yr, driven by Carteyva salesGross profit margin improved t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","VHT","IE00BVYPNV92.GBP","BK1574","MEDX","JDOC","LU0943347566.SGD","IE00BN8TJ469.HKD","ABBV","LU2237443382.USD","LU2237443978.SGD","LU1244550577.SGD","LU1934455277.USD","MADE","REGN","LU0868494617.USD","LU0463099449.HKD","03692","IE0004445239.USD","FHLC","688331","IXJ","IBB","RXL","LU1188198961.HKD","XLV","PJP","LU1037948897.HKD","LU0432979614.USD","FTXH","BBH","AGNG","TBXU","PPH","LU0859254822.USD","LU0949170772.SGD","IBBQ","CMI","LU0395794307.EUR","LU2097828714.EUR","01801","02126","IYH","LU0310799852.SGD","GLAM","LU2362541513.USD","LU1934455863.HKD","TRUH","IE000SO60NU8.SGD","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708397","title":"JW Cayman Therapeutics FY26 H1 IFRS Loss Narrows 81.14% to RMB 50.4 Million; Revenue Rises 4.7% to RMB 111.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708397","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708397?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:58","pubTimestamp":1787824692,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics FY26 H1 IFRS loss narrows 81.14% to RMB 50.4 million; revenue rises 4.7% to RMB 111.4 millionJW Cayman Therapeutics posted IFRS revenue of RMB 111.4 million, up 4.7% year over y","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8Yh1j4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU1974910355.USD","LU2468319806.SGD","TBXU","BK4139","LU0289739699.SGD","LU0109394709.USD","BK4585","BK4588","02126","IBBQ","LU0823416689.USD","BBH","LU2023250504.SGD","LU0058720904.USD","LU0823434583.USD","LU0889565916.HKD","BK1583","LU1917777945.USD","BK1161","LU2362541513.USD","LU2237438978.USD","LU0320765992.SGD","IBB","BK1574","LU0114720955.EUR","LU2106854487.HKD","REGN","LU0882574055.USD","LU0053666078.USD","LU2362540622.SGD","LU0823434740.USD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662877754","title":"Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662877754","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662877754?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:15","pubTimestamp":1787822113,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 CROSSING trial of Tezspire in patients living with eosinophilic esop...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0432979614.USD","BK4581","BK4566","LU1061106388.HKD","BK4533","IE00B2B36J28.USD","LU2112291526.USD","LU1023059063.AUD","LU2237443978.SGD","BIB","BK4585","IBBQ","AZN","LU0128525929.USD","LU2242646821.SGD","PBE","LU2237443465.HKD","LU2456880835.USD","LU2236285917.USD","LU0058720904.USD","BK4007","IE00B3T34201.USD","BK4568","IE0009355771.USD","IBB","LU0889565916.HKD","LU1983299246.USD","BBH","LU0029864427.USD","LU0122379950.USD","LU1829250122.USD","LU1267930573.SGD","LU1571399168.USD","IE0002141913.USD","LU2468319806.SGD","PJP","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2237443895.HKD","BK4588","BK4599","LU0868494617.USD","LU2417539215.USD","TBXU","AZNH","IE00BJJMRZ35.SGD","AMGN","LU1057294990.SGD","LU0320765992.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771175","title":"AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771175","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771175?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:24","pubTimestamp":1787819085,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Amgen  said Thursday their drug Tezspire met the primary endpoints of a Phase 3 trial treating eosinophilic esophagitis, a chronic inflammatory esophagus disorder.The medication met both primary endpoints by reducing tissue inflammation and easing swallowing difficulties at week 24 compared to a placebo, the companies said.The disease and symptom improvements were maintained through week 52 for both tested doses, they said.The companies also said the safety profile of the treatment during the study remained consistent with its previously approved uses.Shares of Amgen were down by over 1% in Thursday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IE00BJT1NW94.SGD","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU1829250122.USD","LU2237443978.SGD","LU2456880835.USD","LU2112291526.USD","BK4534","TBXU","LU2462157665.USD","LU1983299246.USD","LU2242646821.SGD","BBH","LU0109394709.USD","LU0868494617.USD","LU2237443895.HKD","IE00B4R5TH58.HKD","LU0432979614.USD","LU1267930573.SGD","BK4599","BK4585","BK4566","IE00B2B36J28.USD","LU1057294990.SGD","LU2237443549.SGD","LU0289739699.SGD","LU2237443382.USD","LU0128525929.USD","LU0310800379.SGD","LU0708994859.HKD","PBE","AZN","LU1571399168.USD","LU2237443465.HKD","IBBQ","LU0029864427.USD","LU2242652126.USD","BK4533","LU0058720904.USD","LU2089984988.USD","LU0889565916.HKD","LU2237443622.USD","AMGN","AZNH","IBB","IE00BJJMRZ35.SGD","BK4581","PJP","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775710","title":"Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775710?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:55","pubTimestamp":1787813720,"startTime":"0","endTime":"0","summary":"The latest update is out from Vertex Corp. ( ($JP:5290) ). Vertex Corporation has been selected as a constituent of the JPX-Nikkei Mid and Small Ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-corp-added-to-jpx-nikkei-mid-and-small-cap-index-for-fy2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-corp-added-to-jpx-nikkei-mid-and-small-cap-index-for-fy2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999001176.USD","IE00BJT1NW94.SGD","BK4533","LU1585245621.USD","LU1430594728.SGD","LU0234570918.USD","LU0079474960.USD","IE00BZ9MQY76.HKD","LU2456880835.USD","IE0002270589.USD","IE00BJJMRZ35.SGD","IE00B19Z3581.USD","LU2089984988.USD","LU1093756168.USD","SG9999013999.USD","LU1069344957.HKD","LU1778281490.HKD","IDNA","SGXZ57979304.SGD","LU2468319806.SGD","VERX","GNMX","IE00B2B36J28.USD","BK4023","LU0432979614.USD","LU0566484027.USD","LU2417539215.USD","IBB","TBXU","BK4585","IE00BFTCPJ56.SGD","JPX","LU0058720904.USD","LU2462157665.USD","IE00B4R5TH58.HKD","LU1559883803.SGD","BK4567","IBBQ","BIB","LU0289739699.SGD","LU1815336091.USD","PBE","BK4532","IE0002141913.USD","IE00B19Z9Z06.USD","LU0823416689.USD","LU0109394709.USD","VRTX","BBH","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662477574","title":"Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662477574","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662477574?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:55","pubTimestamp":1787813711,"startTime":"0","endTime":"0","summary":"The latest update is out from Vertex Corp. ( ($JP:5290) ). Vertex Corporation has updated its earlier disclosures on changes to directors and offic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-corp-refines-leadership-structure-at-key-subsidiary-vertex-co?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-corp-refines-leadership-structure-at-key-subsidiary-vertex-co?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1430594728.SGD","LU0109394709.USD","BBH","IE00B19Z9P08.USD","IE00BZ9MQY76.HKD","BK4532","LU0234570918.USD","LU2456880835.USD","TBXU","LU2362541513.USD","LU1559883803.SGD","VERX","IE0002270589.USD","SG9999001176.USD","BIB","IBBQ","BK4585","LU0079474960.USD","LU0256863811.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00B19Z3581.USD","IBB","LU0757428866.USD","LU0061475181.USD","LU1815336091.USD","SGXZ57979304.SGD","BK4023","LU0289739699.SGD","IE00B2B36J28.USD","BK4567","LU0058720904.USD","LU0823416689.USD","LU1093756325.SGD","LU2462157665.USD","LU2236285917.USD","BK4533","LU0417517546.SGD","LU0320765992.SGD","LU1035775433.USD","BK4139","VRTX","IDNA","PBE","LU1674673428.USD","LU0566484027.USD","GNMX","LU2417539215.USD","IE00B19Z9Z06.USD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662514775","title":"AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662514775","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662514775?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:40","pubTimestamp":1787812818,"startTime":"0","endTime":"0","summary":"UPDATE 3-AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trialAug 27 (Reuters)-AstraZenecaAZN.Lsaid on Thursday its asthma drug Tezspire met the main goals of a late-stage tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL6N44O0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310799852.SGD","LU1481600234.SGD","LU0792757196.USD","PJP","LU0640478417.SGD","TBXU","BK4588","LU0997586432.USD","LU1170363599.USD","LU2293690082.USD","LU2237443622.USD","PBE","SGXZ57979304.SGD","LU2242652126.USD","AMGN","LU0345777659.USD","LU0823434583.USD","LU1880407132.USD","BK4599","IE00BFTCPJ56.SGD","LU1829250122.USD","BIB","LU0997586515.USD","LU0887340254.USD","LU0077335932.USD","LU0575583348.USD","03165","LU0047473722.EUR","AZN.UK","LU1267930490.SGD","LU1051770623.HKD","LU0661504455.SGD","LU0432979614.USD","IBB","LU0266013472.USD","LU1571399168.USD","LU0972486137.USD","LU1974910355.USD","IBBQ","LU0122379950.USD","BBH","LU0738911758.USD","LU0052756011.USD","LU1003077747.HKD","LU1119994496.HKD","LU1057294990.SGD","LU3187612489.SGD","REGN","LU1153584641.USD","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778025","title":"Amgen - Tezspire Safety Profile Consistent with Approved Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778025?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:00","pubTimestamp":1787810401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA3XV48Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBH","BK4585","BK4599","LU1057294990.SGD","IBBQ","LU1571399168.USD","AMGN","IE00B2B36J28.USD","PJP","BK4534","IE00BJJMRZ35.SGD","PBE","LU2112291526.USD","BK4581","LU0289739699.SGD","TBXU","LU2089984988.USD","LU2468319806.SGD","BK4139","LU2242652126.USD","IBB","LU0122379950.USD","IE0009355771.USD","LU0868494617.USD","LU1061106388.HKD","SG9999001440.SGD","LU0889565916.HKD","BIB","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0320765992.SGD","LU2242646821.SGD","BK4588","LU0058720904.USD","LU1983299246.USD","BK4533","LU1023059063.AUD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0109394709.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662728778","title":"Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662728778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662728778?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:00","pubTimestamp":1787810401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA3XV48Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1571399168.USD","BK4139","LU0058720904.USD","SG9999001440.SGD","BK4599","LU2089984988.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0109394709.USD","BK4533","IE00B4R5TH58.HKD","LU2468319806.SGD","LU0122379950.USD","LU1983299246.USD","IBB","PBE","TBXU","LU0868494617.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","BBH","LU2112291526.USD","BK4585","IE00B2B36J28.USD","LU1061106388.HKD","BK4588","IE0009355771.USD","AMGN","LU2242646821.SGD","LU0320765992.SGD","PJP","LU1023059063.AUD","BK4566","BK4534","LU2242652126.USD","BK4581","IBBQ","BIB","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662872226","title":"Biotron Posts Wider Annual Loss but Boosts Asset Backing Amid Material Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2662872226","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662872226?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:37","pubTimestamp":1787801870,"startTime":"0","endTime":"0","summary":"Biotron ( ($AU:BIT) ) has shared an announcement. Biotron Limited, an ASX-listed Australian biotechnology company, focuses on antiviral drug develo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biotron-posts-wider-annual-loss-but-boosts-asset-backing-amid-material-uncertainty?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biotron-posts-wider-annual-loss-but-boosts-asset-backing-amid-material-uncertainty?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","BK4585","IEIH","IBB","XT","DARP","FWD","JDOC","FHLC","AGNG","BK4588","SYNB","RSPH","LNGR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}